Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402633 | 0.89 | ALDH1A1 (0.70) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL13500479 | 0.81 | KMT2A (0.81) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| Hydrochloric Acid SCHEMBL6442047 | 0.81 | KMT2A (0.79) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL6443105 | 0.80 | KMT2A (0.64) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL7388781 | 0.79 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL6446698 | 0.79 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL6446723 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL3581112 | 0.79 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2AGAAMAPT | |
| SCHEMBL3131935 | 0.78 | TSHR (0.63) | ALDH1A1LMNAKMT2ATSHRKDM4E | |
| SCHEMBL7388778 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAKMT2ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1220856-B1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040152712-A1 | Pharmaceutically active compounds | PFIZER INC. | 2004-08-05 | — | — | US | disclosed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | ALDH1A1 254/4885LMNA 3708/4885KMT2A 4533/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | ALDH1A1 758/4885LMNA 1380/4885KMT2A 4553/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | ALDH1A1 758/4885LMNA 1380/4885KMT2A 4553/4885 |
| US-20040152712-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | ALDH1A1 507/4885LMNA 2113/4885KMT2A 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.